6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Mucosal Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 823 | 2005-06-01 | 2015-10-19 |
| Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma Dacarbazine, Fotemustine, Interferon Alfa-2b - Malignant Melanoma, Recurrent Melanoma | Phase 3 | Completed | National Cancer Institute, Naples | 269 | 2002-04-01 | 2023-04-11 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery Laboratory Biomarker Analysis, Placebo, Sargramostim - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 815 | 2000-02-23 | 2026-06-24 |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Aldesleukin, gp100 Antigen, Montanide ISA 51 VG - Recurrent Melanoma, Stage IIIA Skin Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 185 | 1999-12-01 | 2017-11-20 |
| Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein - Recurrent Melanoma, Stage III Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 216 | 1999-03-01 | 2013-07-16 |
| Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma allovectin-7, allovectin-7/dacarbazine, dacarbazine - Stage IV Melanoma, Stage III Melanoma | Phase 3 | Completed | Vical | 1998-07-01 | 2008-07-25 |
Melanoma (6) · Neoplasms (1) · Skin Neoplasms (1) · Uveal Melanoma (1)
Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Germ Cell and Embryonal (6) · Neoplasms, Nerve Tissue (6) · Neuroectodermal Tumors (6) · Neuroendocrine Tumors (6) · Nevi and Melanomas (6) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6) · Neoplasms (5) · Skin Neoplasms (5) · Eye Diseases (1) · Eye Neoplasms (1) · Uveal Diseases (1) · Uveal Neoplasms (1)
Dacarbazine (2) · Allovectin-7 (1) · Carboplatin (1) · Colony-Stimulating Factors (1) · Interferon alpha-2 (1) · Interleukin-2 (1) · Melphalan (1) · Paclitaxel (1) · Sorafenib (1) · Taxes (1) · Tumor Necrosis Factor-alpha (1) · Tumor Necrosis Factors (1) · aldesleukin (1) · fotemustine (1) · gp100 Melanoma Antigen (1)
National Cancer Institute (NCI) (4) · National Cancer Institute, Naples (1) · Vical (1)
United States (5) · Australia (1)
Antonio Daponte, M.D. (1) · Cherie Smith (1) · David H Lawson (1) · Douglas Fraker (1) · Douglas Schwartzentruber (1) · Keith Flaherty (1) · Paolo A Ascierto, M.D., Ph.D. (1) · Simona Signoriello, M.D. (1)
PMID 21631324, PMID 23248256, PMID 23402397, PMID 26351350
U10CA021115 (2), U10CA076001 (1), U10CA180820 (1)